Literature DB >> 23726162

The Global Drug Facility and its role in the market for tuberculosis drugs.

Nimalan Arinaminpathy1, Thierry Cordier-Lassalle, Anant Vijay, Christopher Dye.   

Abstract

Universal access to high-quality treatment is central to the Global Plan to Stop TB. The Global Drug Facility (GDF) was launched in 2001 to help to achieve this goal, through services including the supply of affordable, quality-assured drugs to countries in need. We assess the scale of GDF drug supplies worldwide and find that the GDF commands a substantial proportion of the market for drugs for first-line and second-line treatment regimens, having supplied, for example, first-line drugs for roughly 35% of cases reported worldwide in 2011. Significant potential remains for GDF expansion, especially in the provision of second-line drugs, which would be aided by future increases in case detection.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23726162     DOI: 10.1016/S0140-6736(13)60896-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

Review 1.  Quality of drug-resistant tuberculosis care: Gaps and solutions.

Authors:  Zarir Udwadia; Jennifer Furin
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2019-04-24

2.  Quality assurance in anti-tuberculosis drug procurement by the Stop TB Partnership-Global Drug Facility: Procedures, costs, time requirements, and comparison of assay and dissolution results by manufacturers and by external analysis.

Authors:  Cathrin Hauk; Simon Schäfermann; Peter Martus; Nigorsulton Muzafarova; Magali Babaley; Brenda Waning; Lutz Heide
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

3.  Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan.

Authors:  Stefan Kohler; Norman Sitali; Jay Achar; Nicolas Paul
Journal:  ERJ Open Res       Date:  2022-03-21

4.  Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility.

Authors:  Kaspars Lunte; Thierry Cordier-Lassalle; Joel Keravec
Journal:  Bull World Health Organ       Date:  2015-02-27       Impact factor: 9.408

5.  The Global Drug Facility as an intervention in the market for tuberculosis drugs.

Authors:  Nimalan Arinaminpathy; Thierry Cordier-Lassalle; Kaspars Lunte; Christopher Dye
Journal:  Bull World Health Organ       Date:  2015-03-03       Impact factor: 9.408

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.